O	0	10	Randomized
O	11	21	controlled
O	22	27	trial
O	28	30	of
B-intervention	31	38	aerobic
I-intervention	39	47	exercise
O	48	50	on
O	51	58	insulin
O	59	62	and
O	63	70	insulin
O	70	71	-
O	71	75	like
O	76	82	growth
O	83	90	factors
O	91	93	in
O	94	100	breast
O	101	107	cancer
O	108	117	survivors
O	117	118	:
O	119	122	the
O	123	127	Yale
O	128	136	Exercise
O	137	140	and
O	141	153	Survivorship
O	154	159	study
O	159	160	.

O	161	165	High
O	166	173	insulin
O	174	177	and
O	178	185	insulin
O	185	186	-
O	186	190	like
O	191	197	growth
O	198	204	factor
O	204	205	-
O	205	206	I
O	207	208	(
O	208	211	IGF
O	211	212	-
O	212	213	I
O	213	214	)
O	215	221	levels
O	222	225	may
O	226	228	be
O	229	239	associated
O	240	244	with
O	245	247	an
O	248	257	increased
O	258	264	breast
O	265	271	cancer
O	272	276	risk
O	277	280	and
O	280	281	/
O	281	283	or
O	284	289	death
O	289	290	.

O	291	296	Given
O	297	300	the
O	301	305	need
O	306	308	to
O	309	317	identify
O	318	328	modifiable
O	329	336	factors
O	337	341	that
O	342	350	decrease
O	351	358	insulin
O	358	359	,
O	360	363	IGF
O	363	364	-
O	364	365	I
O	365	366	,
O	367	370	and
O	371	377	breast
O	378	384	cancer
O	385	389	risk
O	390	393	and
O	394	399	death
O	399	400	,
O	401	403	we
O	404	416	investigated
O	417	420	the
O	421	428	effects
O	429	431	of
O	432	433	a
O	434	435	6
O	435	436	-
O	436	441	month
O	442	452	randomized
O	453	463	controlled
O	464	471	aerobic
O	472	480	exercise
O	481	493	intervention
O	494	500	versus
O	501	506	usual
O	507	511	care
O	512	514	on
O	515	522	fasting
O	523	530	insulin
O	530	531	,
O	532	535	IGF
O	535	536	-
O	536	537	I
O	537	538	,
O	539	542	and
O	543	546	its
O	547	554	binding
O	555	562	protein
O	563	564	(
O	564	569	IGFBP
O	569	570	-
O	570	571	3
O	571	572	)
O	573	575	in
O	576	590	postmenopausal
O	591	597	breast
O	598	604	cancer
O	605	614	survivors
O	614	615	.

B-total-participants	616	623	Seventy
I-total-participants	623	624	-
I-total-participants	624	628	five
B-eligibility	629	643	postmenopausal
I-eligibility	644	650	breast
I-eligibility	651	657	cancer
I-eligibility	658	667	survivors
O	668	672	were
O	673	683	identified
O	684	688	from
O	689	692	the
O	693	697	Yale
O	697	698	-
B-location	698	701	New
I-location	702	707	Haven
O	708	716	Hospital
O	717	722	Tumor
O	723	731	Registry
O	732	735	and
O	736	744	randomly
O	745	753	assigned
O	754	756	to
O	757	759	an
O	760	768	exercise
O	769	770	(
O	770	771	n
O	772	773	=
B-intervention	774	776	37
O	776	777	)
O	778	780	or
B-control	781	786	usual
I-control	787	791	care
O	792	793	(
O	793	794	n
O	795	796	=
B-control-participants	797	799	38
O	799	800	)
O	801	806	group
O	806	807	.

O	808	811	The
O	812	820	exercise
O	821	826	group
O	827	839	participated
O	840	842	in
O	843	846	150
O	847	854	minutes
O	855	858	per
O	859	863	week
O	864	866	of
O	867	875	moderate
O	875	876	-
O	876	885	intensity
O	886	893	aerobic
O	894	902	exercise
O	902	903	.

O	904	907	The
O	908	913	usual
O	914	918	care
O	919	924	group
O	925	928	was
O	929	939	instructed
O	940	942	to
O	943	951	maintain
O	952	957	their
O	958	965	current
O	966	974	physical
O	975	983	activity
O	984	989	level
O	989	990	.

O	991	992	A
O	993	1000	fasting
O	1001	1006	blood
O	1007	1013	sample
O	1014	1017	was
O	1018	1027	collected
O	1028	1030	on
O	1031	1035	each
O	1036	1041	study
O	1042	1053	participant
O	1054	1056	at
O	1057	1065	baseline
O	1066	1069	and
O	1070	1071	6
O	1072	1078	months
O	1078	1079	.

O	1080	1085	Blood
O	1086	1092	levels
O	1093	1095	of
O	1096	1103	insulin
O	1104	1107	and
O	1108	1111	IGF
O	1112	1116	were
O	1117	1125	measured
O	1126	1130	with
O	1131	1136	ELISA
O	1136	1137	.

O	1138	1140	On
O	1141	1148	average
O	1148	1149	,
O	1150	1160	exercisers
B-outcome	1161	1170	increased
I-outcome	1171	1178	aerobic
I-outcome	1179	1187	exercise
O	1188	1190	by
B-iv-cont-mean	1191	1194	129
I-iv-cont-mean	1195	1202	minutes
O	1203	1206	per
O	1207	1211	week
O	1212	1220	compared
O	1221	1225	with
B-cv-cont-mean	1226	1228	45
I-cv-cont-mean	1229	1236	minutes
O	1237	1240	per
O	1241	1245	week
O	1246	1251	among
O	1252	1257	usual
O	1258	1262	care
O	1263	1275	participants
O	1276	1277	(
O	1277	1278	P
O	1279	1280	<
O	1281	1282	0
O	1282	1283	.
O	1283	1286	001
O	1286	1287	)
O	1287	1288	.

O	1289	1294	Women
O	1295	1305	randomized
O	1306	1308	to
O	1309	1317	exercise
O	1318	1329	experienced
O	1330	1339	decreases
O	1340	1342	in
B-outcome	1343	1350	insulin
O	1350	1351	,
B-outcome	1352	1355	IGF
I-outcome	1355	1356	-
I-outcome	1356	1357	I
O	1357	1358	,
O	1359	1362	and
B-outcome	1363	1368	IGFBP
I-outcome	1368	1369	-
I-outcome	1369	1370	3
O	1370	1371	,
O	1372	1379	whereas
O	1380	1385	women
O	1386	1396	randomized
O	1397	1399	to
O	1400	1405	usual
O	1406	1410	care
O	1411	1414	had
O	1415	1424	increases
O	1425	1427	in
O	1428	1433	these
O	1434	1442	hormones
O	1442	1443	.

O	1444	1451	Between
O	1451	1452	-
O	1452	1457	group
O	1458	1469	differences
O	1470	1472	in
B-outcome	1473	1480	insulin
I-outcome	1480	1481	,
I-outcome	1482	1485	IGF
I-outcome	1485	1486	-
I-outcome	1486	1487	I
I-outcome	1487	1488	,
I-outcome	1489	1492	and
I-outcome	1493	1498	IGFBP
I-outcome	1498	1499	-
I-outcome	1499	1500	3
O	1501	1505	were
O	1506	1508	20
O	1508	1509	.
O	1509	1510	7
O	1510	1511	%
O	1512	1513	(
O	1513	1514	P
O	1515	1516	=
O	1517	1518	0
O	1518	1519	.
O	1519	1522	089
O	1522	1523	)
O	1523	1524	,
O	1525	1526	8
O	1526	1527	.
O	1527	1528	9
O	1528	1529	%
O	1530	1531	(
O	1531	1532	P
O	1533	1534	=
O	1535	1536	0
O	1536	1537	.
O	1537	1540	026
O	1540	1541	)
O	1541	1542	,
O	1543	1546	and
O	1547	1548	7
O	1548	1549	.
O	1549	1550	9
O	1550	1551	%
O	1552	1553	(
O	1553	1554	P
O	1555	1556	=
O	1557	1558	0
O	1558	1559	.
O	1559	1562	006
O	1562	1563	)
O	1563	1564	,
O	1565	1577	respectively
O	1577	1578	.

O	1579	1587	Moderate
O	1587	1588	-
O	1588	1597	intensity
O	1598	1605	aerobic
O	1606	1614	exercise
O	1614	1615	,
O	1616	1620	such
O	1621	1623	as
O	1624	1629	brisk
O	1630	1637	walking
O	1637	1638	,
O	1639	1648	decreases
B-outcome	1649	1652	IGF
I-outcome	1652	1653	-
I-outcome	1653	1654	I
I-outcome	1655	1658	and
I-outcome	1659	1664	IGFBP
I-outcome	1664	1665	-
I-outcome	1665	1666	3
O	1666	1667	.

O	1668	1671	The
O	1672	1680	exercise
O	1680	1681	-
O	1681	1688	induced
O	1689	1698	decreases
O	1699	1701	in
O	1702	1705	IGF
O	1706	1709	may
O	1710	1717	mediate
O	1718	1721	the
O	1722	1730	observed
O	1731	1742	association
O	1743	1750	between
O	1751	1757	higher
O	1758	1764	levels
O	1765	1767	of
O	1768	1776	physical
O	1777	1785	activity
O	1786	1789	and
O	1790	1798	improved
O	1799	1807	survival
O	1808	1810	in
O	1811	1816	women
O	1817	1826	diagnosed
O	1827	1831	with
O	1832	1838	breast
O	1839	1845	cancer
O	1845	1846	.
